The demand for noninvasive prenatal tests will nearly triple over the next 6 years, according to market researchers, reaching $3.6 billion in 2019 as more and more diagnostics outfits contend for dominance. According to Transparency Market Research, the prenatal space will grow roughly 38% a year as physicians and patients warm up to the safety and efficacy of tests from the likes of Sequenom ($SQNM), Natera and Illumina's ($ILMN) Verinata Health. More